1.Evidence-based on Mendelian randomization:causal relationship between plasma lipids and different subtypes of lung cancer
Wei ZHANG ; Jian GAO ; Yi TONG ; Yu GAN
Tumor 2025;45(1):22-34
Objective:To Evaluate the potential causal relationship between the levels of 179 lipids in peripheral blood and the risk of different subtypes of lung cancer by Mendelian randomization analysis.Methods:A two-sample Mendelian randomization analysis was performed using data from the Genome-Wide Association Study(GWAS),and sensitivity analysis was performed to verify the reliability of the results.Single nucleotide polymorphisms(SNPs)were used as instrumental variables,and GWAS data for different subtypes of lung cancer were used as outcome variables.We analyze potential causal associations between the levels of 179 lipids and the risk of different subtypes of lung cancer.Results:The causal relationship between phosphatidylcholine and lung adenocarcinoma was established as a protective factor,and Sphingomyelin and Triacylglycerol have been identified as being linked to lung adenocarcinoma and function as risk factors.Phosphatidylcholine were found to have a causal association with lung squamous cell carcinoma serving as a protective factor,and Phosphatidylethanolamine and Sphingomyelin were identified as risk factors for lung squamous cell carcinoma.However,the effects of different subtypes of Phosphatidylcholine on lung adenocarcinoma and lung squamous cell carcinoma were different.The study did not find evidence that lipids can influence small cell lung carcinoma.Conclusion:This study provides evidence of a causal relationship between lipids level features and different subtypes of lung cancer.
2.Fusion of Dual-targeting Peptides with MAP30 Promotes the Apoptosis of MDA-MB-231 Breast Cancer Cells
Yi-Xuan YANG ; Xin-Yi WANG ; Wei-Wei CHEN ; Li GAN ; Yu SUN ; Tong LIN ; Wei-Chun ZHAO ; Zhen-Hong ZHU
Chinese Journal of Biochemistry and Molecular Biology 2025;41(2):260-272
Momordica antiviral protein 30 kD(MAP30)is a type Ⅰ ribosome-inactivating protein(RIP)with antibacterial,anti-HIV and antitumor activities but lacks the ability to target tumor cells.To in-crease its tumor-targeting ability,the arginine-glycine-aspartic(RGD)peptide and the epidermal growth factor receptor interference(EGFRi)peptide were fused with MAP30,which was named ELRL-MAP30.The efficiency of targeted therapy for triple-negative breast cancer(TNBC)MDA-MB-231 cells,which lack the expression of estrogen receptor(ER),Progesterone receptor(PgR)and human epidermal growth factor receptor-2(HER2),is limited.In this study,we focus on exploring the effect and mecha-nism of ELRL-MAP30 on TNBC MDA-MB-231 cells.First,we discovered that ELRL-MAP30 significant-ly inhibited the migration and invasion of MDA-MB-231 cells and induced MDA-MB-231 cell apoptosis.Moreover,ELRL-MAP30 treatment resulted in a significant increase in Bax expression and a decrease in Bcl-2 expression.Furthermore,ELRL-MAP30 triggered apoptosis via the Fak/EGFR/Erk and Ilk/Akt signaling pathways.In addition,recombinant ELRL-MAP30 can inhibit chicken embryonic angiogenesis,and also inhibit the tube formation ability of human umbilical vein endothelial cells(HUVECs),indica-ting its potential therapeutic effects on tumor angiogenesis.Collectively,these results indicate that ELRL-MAP30 has significant tumor-targeting properties in MDA-MB-231 cancer cells and reveals potential ther-apeutic effects on angiogenesis.These findings indicate the potential role of ELRL-MAP30 in the targeted treatment of the TNBC cell line MDA-MB-231.
3.Evidence-based on Mendelian randomization:causal relationship between plasma lipids and different subtypes of lung cancer
Wei ZHANG ; Jian GAO ; Yi TONG ; Yu GAN
Tumor 2025;45(1):22-34
Objective:To Evaluate the potential causal relationship between the levels of 179 lipids in peripheral blood and the risk of different subtypes of lung cancer by Mendelian randomization analysis.Methods:A two-sample Mendelian randomization analysis was performed using data from the Genome-Wide Association Study(GWAS),and sensitivity analysis was performed to verify the reliability of the results.Single nucleotide polymorphisms(SNPs)were used as instrumental variables,and GWAS data for different subtypes of lung cancer were used as outcome variables.We analyze potential causal associations between the levels of 179 lipids and the risk of different subtypes of lung cancer.Results:The causal relationship between phosphatidylcholine and lung adenocarcinoma was established as a protective factor,and Sphingomyelin and Triacylglycerol have been identified as being linked to lung adenocarcinoma and function as risk factors.Phosphatidylcholine were found to have a causal association with lung squamous cell carcinoma serving as a protective factor,and Phosphatidylethanolamine and Sphingomyelin were identified as risk factors for lung squamous cell carcinoma.However,the effects of different subtypes of Phosphatidylcholine on lung adenocarcinoma and lung squamous cell carcinoma were different.The study did not find evidence that lipids can influence small cell lung carcinoma.Conclusion:This study provides evidence of a causal relationship between lipids level features and different subtypes of lung cancer.
4.Fusion of Dual-targeting Peptides with MAP30 Promotes the Apoptosis of MDA-MB-231 Breast Cancer Cells
Yi-Xuan YANG ; Xin-Yi WANG ; Wei-Wei CHEN ; Li GAN ; Yu SUN ; Tong LIN ; Wei-Chun ZHAO ; Zhen-Hong ZHU
Chinese Journal of Biochemistry and Molecular Biology 2025;41(2):260-272
Momordica antiviral protein 30 kD(MAP30)is a type Ⅰ ribosome-inactivating protein(RIP)with antibacterial,anti-HIV and antitumor activities but lacks the ability to target tumor cells.To in-crease its tumor-targeting ability,the arginine-glycine-aspartic(RGD)peptide and the epidermal growth factor receptor interference(EGFRi)peptide were fused with MAP30,which was named ELRL-MAP30.The efficiency of targeted therapy for triple-negative breast cancer(TNBC)MDA-MB-231 cells,which lack the expression of estrogen receptor(ER),Progesterone receptor(PgR)and human epidermal growth factor receptor-2(HER2),is limited.In this study,we focus on exploring the effect and mecha-nism of ELRL-MAP30 on TNBC MDA-MB-231 cells.First,we discovered that ELRL-MAP30 significant-ly inhibited the migration and invasion of MDA-MB-231 cells and induced MDA-MB-231 cell apoptosis.Moreover,ELRL-MAP30 treatment resulted in a significant increase in Bax expression and a decrease in Bcl-2 expression.Furthermore,ELRL-MAP30 triggered apoptosis via the Fak/EGFR/Erk and Ilk/Akt signaling pathways.In addition,recombinant ELRL-MAP30 can inhibit chicken embryonic angiogenesis,and also inhibit the tube formation ability of human umbilical vein endothelial cells(HUVECs),indica-ting its potential therapeutic effects on tumor angiogenesis.Collectively,these results indicate that ELRL-MAP30 has significant tumor-targeting properties in MDA-MB-231 cancer cells and reveals potential ther-apeutic effects on angiogenesis.These findings indicate the potential role of ELRL-MAP30 in the targeted treatment of the TNBC cell line MDA-MB-231.
5.The Role and Positioning of Clinical Trial Ethics Review under Pharmaceutical Innovation Strategy
Zhonglin CHEN ; Gan HE ; Yu FENG ; Huihui HAN ; Yao YAO ; Ning ZHENG
Chinese Medical Ethics 2023;36(2):180-185
Ethical review runs through the whole process of drug clinical trials, and is a critical step to ensure the rights and interests of subjects. This paper analyzed and discussed the role and positioning of ethical review in new drug clinical trials, cleared the principles of ethical review, identified the responsibilities of ethical review, and clarified the authority of ethical review approval documents. The ethical review should primarily focus on the ethics of the clinical trials, not replace other professional institutions to review the clinical trials’ legality and scientific nature. Ethical approval is only one of the necessary conditions for conducting clinical trials, not the only factor. It is recommended to strengthen the publicity and popularization of scientific and technological ethics awareness, improve the clinical trial approval mechanism, and optimize the phrasing of ethical review approval documents. It is warranted to further optimize the quality of ethical review, improve the construction of ethical review system, ultimately achieve the unity of promoting innovation and preventing risks, so as to effectively realize the benign interaction between high-quality development of scientific and technological innovation and high-level safety.
6.Principles and strategies for species identification based on analysis of whole-genome
Yu-tong GAN ; Tian-yi XIN ; Wen-jie XU ; Li-jun HAO ; Gui-hong QI ; Qian LOU ; Jing-yuan SONG
Acta Pharmaceutica Sinica 2023;58(8):2364-2374
The main sources of natural drugs include various biological species such as plants, animals, and microorganisms. The accurate identification of these species is the bedrock of natural drug development. We propose a novel method of species identification in this paper: analysis of whole-genome (AGE), a molecular diagnostic method used to identify species by finding species-specific sequences from the whole genome and precisely recognizing the specific target sequences. We elaborate that the principle for species identification based on AGE is that the genome sequences of diverse species must differ and divide the implementation strategy of the method into two levels of research and application. Based on our analysis of its characteristics, the method would have the potential advantages of reliable principle, high specificity, and wide applicability. Moreover, three crucial concerns related to building method systems including genome acquisition, bioinformatics analysis, and database construction, are further discussed. In summary, we offer theoretical underpinnings and methodological guidance for the development of bioinformatics software and commercial kits, indicating AGE has great application potential in objects, subjects, and industries.
7.Related factors of negative conversion time of nucleic acid in children with COVID-19.
Yu Feng LI ; Jian Hua ZHANG ; Han GAN ; Kai Chuang ZHANG ; Kang CAI ; Wei LIU ; Sheng Nan LUO ; Hong Li JIANG ; Biao JIN ; Li Bin ZHAO ; Kun SUN
Chinese Journal of Pediatrics 2023;61(3):256-260
Objective: To explore the related factors of negative conversion time (NCT) of nucleic acid in children with COVID-19. Methods: A retrospective cohort study was conducted. A total of 225 children who were diagnosed with COVID-19 and admitted to Changxing Branch of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from April 3rd to May 31st 2022 were enrolled in the study. The infection age, gender, viral load, basic disease, clinical symptoms and information of accompanying caregivers were retrospectively analyzed. According to age, the children were divided into<3 years of age group and 3-<18 years of age group. According to the viral nucleic acid test results, the children were divided into positive accompanying caregiver group and negative accompanying caregiver group. Comparisons between groups were performed using Mann-Whitney U test or Chi-square test. Multivariate Logistic regression analysis was used to analyze the related factors of NCT of nucleic acid in children with COVID-19. Results: Among the 225 patients (120 boys and 105 girls) of age 2.8 (1.3, 6.2) years, 119 children <3 years and 106 children 3-<18 years of age, 19 cases were diagnosed with moderate COVID-19, and the other 206 cases were diagnosed with mild COVID-19. There were 141 patients in the positive accompanying caregiver group and 84 patients in the negative accompanying caregiver group.Patients 3-<18 years of age had a shorter NCT (5 (3, 7) vs.7 (4, 9) d, Z=-4.17, P<0.001) compared with patients <3 years of age. Patients in the negative accompanying caregiver group had a shorter NCT (5 (3, 7) vs.6 (4, 9) d,Z=-2.89,P=0.004) compared with patients in the positive accompanying caregiver group. Multivariate Logistic regression analysis showed that anorexia was associated with NCT of nucleic acid (OR=3.74,95%CI 1.69-8.31, P=0.001). Conclusion: Accompanying caregiver with positive nucleic acid test may prolong NCT of nucleic acid, and decreased appetite may be associated with prolonged NCT of nucleic acid in children with COVID-19.
Adolescent
;
Child
;
Child, Preschool
;
Female
;
Humans
;
Male
;
Young Adult
;
China/epidemiology*
;
COVID-19/genetics*
;
Nucleic Acids
;
Retrospective Studies
8.Nanopolyphenol rejuvenates microglial surveillance of multiple misfolded proteins through metabolic reprogramming.
Dayuan WANG ; Xiao GU ; Xinyi MA ; Jun CHEN ; Qizhi ZHANG ; Zhihua YU ; Juan LI ; Meng HU ; Xiaofang TAN ; Yuyun TANG ; Jianrong XU ; Minjun XU ; Qingxiang SONG ; Huahua SONG ; Gan JIANG ; Zaiming TANG ; Xiaoling GAO ; Hongzhuan CHEN
Acta Pharmaceutica Sinica B 2023;13(2):834-851
Microglial surveillance plays an essential role in clearing misfolded proteins such as amyloid-beta, tau, and α-synuclein aggregates in neurodegenerative diseases. However, due to the complex structure and ambiguous pathogenic species of the misfolded proteins, a universal approach to remove the misfolded proteins remains unavailable. Here, we found that a polyphenol, α-mangostin, reprogrammed metabolism in the disease-associated microglia through shifting glycolysis to oxidative phosphorylation, which holistically rejuvenated microglial surveillance capacity to enhance microglial phagocytosis and autophagy-mediated degradation of multiple misfolded proteins. Nanoformulation of α-mangostin efficiently delivered α-mangostin to microglia, relieved the reactive status and rejuvenated the misfolded-proteins clearance capacity of microglia, which thus impressively relieved the neuropathological changes in both Alzheimer's disease and Parkinson's disease model mice. These findings provide direct evidences for the concept of rejuvenating microglial surveillance of multiple misfolded proteins through metabolic reprogramming, and demonstrate nanoformulated α-mangostin as a potential and universal therapy against neurodegenerative diseases.
9.Analysis and Discussion on the Ethical Pre-review Model of Clinical Trials under the Pharmaceutical Innovation Strategy
Zhonglin CHEN ; Gan HE ; Yu FENG ; Huihui HAN ; Yao YAO ; Ning ZHENG
Chinese Medical Ethics 2022;35(11):1214-1217
With the implementation of the national biomedical innovation strategy, new requirements for ethical review of clinical trials have been put forward, and more attention has been paid to the ethical pre-review. Based on the current situation of clinical trials and ethical review of new drugs in China, this paper discussed the concept, advantages and necessity of ethical pre-review, sorted out the problems and challenges in the implementation of ethical pre-review at this stage, and put forward the following suggestions on how to better implement ethical pre-review in clinical trials under the pharmaceutical innovation strategy: the complete definition of "ethical pre-review" should be made clearly; ethical review should be carried out on the basis of necessary reference; the scope of application of ethical pre-review should be clarified; after the ethical pre-review, the statement of the approval document should be standardized and accurate.
10.Asthma treatment adherence and related factors in Shanghai, China.
Juan DU ; Yu-Heng SHI ; Yu-Xiang DUAN ; Xiao-Ru WANG ; Min ZHOU ; Wen-Chao GU ; Chi-Jun WEN ; Yi GONG ; Chun-Ling DU ; Bo PENG ; Lin SUN ; Wei TANG
Chinese Medical Journal 2021;134(20):2506-2508

Result Analysis
Print
Save
E-mail